Cardiovascular

AstraZeneca has been driving cardiovascular innovation for more than 100 years. Our enduring goal is to push the boundaries of science to further reduce cardiovascular morbidity and mortality beyond current treatments, and to deliver transformative cardiovascular medicines to the people who need them.

  • Brilique (ticagrelor) 90MG B.D. in combination with ASA is indicated for use in a wide range of ACS patients [1-3]

References

1. Wallentin L et al. N. Engl J Med 2009; 361: 1045-1057
2. Lindholm D et al. Eur Heart J 2014; 35: 2083-2093
3. AstraZeneca BRILIQUE (ticagrelor) Summary of Product Characteristics. Available from www.medicines.org.uk/emc (last accessed August 2017)

GB-12085 - May 2018